Simultaneous Establishment of Autologous Colorectal Cancer and Mesothelial Stromal Cell Lines from Malignant Ascites Reveals a Mesothelial-Stromal FGFR3 Axis as a Potential Vulnerability in Peritoneal Metastasis
A patient-derived tumor model reveals a vulnerability in cancer's spread to the abdomen, opening new treatment possibilities.
Novel autologous paired CRC-mesothelial cell model from a single patient's malignant ascites reveals a stromal FGFR3 axis that promotes peritoneal metastasis, with FGFR inhibition reducing tumor growth in xenograft models. This preclinical finding identifies a potential therapeutic vulnerability in CRC peritoneal dissemination, an area of high unmet need.
What the study was
- Study design
- Preclinical (in vitro and in vivo xenograft, cell line establishment)
- Sample size
- 1
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
Novel autologous CRC-mesothelial model identifies FGFR3 as therapeutic target in peritoneal metastasis; single-patient derivation limits translational conclusions but mechanistic novelty is high.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.